Dr van Tienhoven presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the PREOPANC-1 trial.

This was a phase III randomised trial in which patients with resectable pancreatic cancer received 10 weeks of chemoradiotherapy prior to surgery, or immediate surgery alone.

Median overall survival improved from 13.7 months to 17.1, disease recurrence from 7.9 months to 9.9 months, and two year survival rate from 30% to 42%

For more on these results, watch his interview with ecancer, or read news coverage here.

View the slides here.